Stock Analysis on Net
Stock Analysis on Net

Merck & Co. Inc. (NYSE:MRK)

$24.99

Analysis of Short-term (Operating) Activity Ratios
Quarterly Data

Microsoft Excel

Paying user area


We accept:

Visa Mastercard Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check

Short-term Activity Ratios (Summary)

Merck & Co. Inc., short-term (operating) activity ratios (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Turnover Ratios
Inventory turnover
Receivables turnover
Payables turnover
Working capital turnover
Average No. Days
Average inventory processing period
Add: Average receivable collection period
Operating cycle
Less: Average payables payment period
Cash conversion cycle

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The analysis of short-term operating activity reveals a fluctuating trend in efficiency, characterized by a notable expansion of the operating cycle through mid-2025 followed by a recovery phase in 2026. The overall operational efficiency was primarily influenced by inventory management and the strategic timing of payables.

Inventory Management Efficiency
Inventory turnover exhibited a general decline from a peak of 3.10 in September 2022 to a low of 2.25 in June 2025. This contraction corresponds with an increase in the average inventory processing period, which rose from 133 days in March 2022 to a peak of 162 days in June 2025. However, a significant recovery is observed in the first half of 2026, with turnover returning to 2.90 and the processing period dropping to 126 days, suggesting improved inventory throughput.
Receivables and Collection Performance
Receivables turnover remained relatively stable, fluctuating within a narrow band between 5.29 and 6.27. The average receivable collection period showed minimal volatility, generally oscillating between 58 and 69 days. This consistency indicates a disciplined and predictable credit collection process throughout the analyzed period.
Payables and Obligations Management
A downward trend in payables turnover was observed from March 2022 through September 2025, reaching a low of 3.53. This trend reflects a strategic extension of the average payables payment period, which increased from 86 days to a peak of 103 days in September 2025. In 2026, this trend reversed sharply, with the payment period decreasing to 78 days by June 2026, indicating a shift toward faster settlement of obligations.
Operating and Cash Conversion Cycles
The operating cycle lengthened from 199 days in March 2022 to 230 days in June 2025, driven largely by the slower movement of inventory. The cash conversion cycle (CCC) followed a similar trajectory, peaking at 138 days in the first half of 2024. While the extension of payables provided a partial buffer, the CCC remained elevated until 2026, when it moderated to 117 days, signaling a reduction in the time required to convert resource inputs into cash flows.
Working Capital Utilization
Working capital turnover demonstrated significant volatility, reaching a high of 9.68 in March 2024 before dropping to a low of 3.39 in September 2025. This variance suggests periodic shifts in the efficiency with which working capital is deployed to generate revenue, with a marked recovery observed in the 2026 data.

Turnover Ratios


Average No. Days



Inventory Turnover

Merck & Co. Inc., inventory turnover calculation (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Cost of sales
Inventories, excludes inventories classified in Other assets
Short-term Activity Ratio
Inventory turnover1
Benchmarks
Inventory Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Inventory turnover = (Cost of salesQ2 2026 + Cost of salesQ1 2026 + Cost of salesQ4 2025 + Cost of salesQ3 2025) ÷ Inventories, excludes inventories classified in Other assets
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The analysis of inventory activity reveals a cyclical pattern characterized by a prolonged period of declining efficiency followed by a notable recovery in the latter stages of the observed period. The inventory turnover ratio exhibited a general downward trajectory from a peak of 3.10 in September 2022 to a minimum of 2.25 in June 2025, before rebounding to 2.90 by June 2026.

Inventory Turnover Ratio Dynamics
A consistent deceleration in turnover efficiency is observed between March 2023 and June 2025. During this window, the ratio fell from 2.72 to 2.25, indicating a slowing rate of inventory liquidation relative to the cost of goods sold. This trend reversed sharply in late 2025 and early 2026, with the ratio climbing back toward 3.00, suggesting improved operational efficiency or a strategic shift in inventory management.
Inventory Level Trends
Inventory balances showed a steady upward trend for much of the period, rising from 5,774 million US dollars in March 2022 to a peak of 6,658 million US dollars in December 2025. The growth in held assets contributed to the decline in the turnover ratio during the 2023-2025 period. However, a contraction in inventory levels occurred in the first half of 2026, ending at 6,207 million US dollars, which supported the recovery of the turnover ratio.
Cost of Sales Correlation
Cost of sales remained relatively stable, fluctuating mostly between 3,500 million and 4,300 million US dollars for several years. A significant anomaly is observed in December 2025, where cost of sales spiked to 5,551 million US dollars. This surge in expenditure directly correlated with a jump in the inventory turnover ratio to 2.46, demonstrating that the increase in sales volume or cost of goods sold effectively cleared accumulated inventory levels.

In summary, the operating activity ratios indicate that the organization experienced a period of inventory accumulation that weighed on turnover efficiency until late 2025. The subsequent increase in cost of sales and the reduction in overall inventory levels have restored the turnover ratio to levels consistent with the 2022 performance.



Receivables Turnover

Merck & Co. Inc., receivables turnover calculation (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Sales
Accounts receivable, net of allowance for doubtful accounts
Short-term Activity Ratio
Receivables turnover1
Benchmarks
Receivables Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Receivables turnover = (SalesQ2 2026 + SalesQ1 2026 + SalesQ4 2025 + SalesQ3 2025) ÷ Accounts receivable, net of allowance for doubtful accounts
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The financial data indicates a general decline in the efficiency of receivables collection over the observed period from March 2022 through June 2026, characterized by a slower rate of revenue growth relative to the increase in outstanding accounts receivable.

Sales Performance
Quarterly sales exhibited moderate volatility with a general upward trajectory. Revenue fluctuated between a low of 13,830 million USD in December 2022 and a peak of 17,276 million USD in September 2025. While sales grew from 15,901 million USD at the start of the period to 16,607 million USD by June 2026, the growth was non-linear and subject to quarterly variations.
Accounts Receivable Trends
A consistent increase in net accounts receivable is observed. Balances rose from 9,828 million USD in March 2022 to 12,564 million USD by June 2026. This represents a steady expansion in the volume of outstanding credit extended to customers, with a notable acceleration in the balance starting in the first quarter of 2023.
Receivables Turnover Ratio Analysis
The receivables turnover ratio peaked at 6.27 in December 2022, marking the period of highest collection efficiency. Following this peak, a downward trend is observable, with the ratio primarily oscillating between 5.30 and 5.92 throughout 2023, 2024, and 2025. The ratio concluded the period at 5.30 in June 2026. This contraction in the turnover ratio confirms that the growth in accounts receivable has outpaced the growth in sales, resulting in a longer average collection cycle.


Payables Turnover

Merck & Co. Inc., payables turnover calculation (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Cost of sales
Trade accounts payable
Short-term Activity Ratio
Payables turnover1
Benchmarks
Payables Turnover, Competitors2
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Payables turnover = (Cost of salesQ2 2026 + Cost of salesQ1 2026 + Cost of salesQ4 2025 + Cost of salesQ3 2025) ÷ Trade accounts payable
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The analysis of short-term operating activity reveals a fluctuating pattern in payables turnover from March 2022 through June 2026. While cost of sales and trade accounts payable exhibited periods of synchronized growth, the turnover ratio showed a general downward trajectory through 2024 and 2025 before experiencing a notable recovery in the first half of 2026.

Cost of Sales and Trade Payables Correlation
Cost of sales generally ranged between 3,419 million and 5,551 million US dollars. A significant peak in cost of sales occurred in December 2025, which coincided with the period's highest trade accounts payable balance of 4,404 million US dollars. This positive correlation indicates that increases in production and procurement expenses were largely supported by an increase in short-term supplier credit.
Payables Turnover Trend Analysis
The payables turnover ratio reached its peak of 5.16 in September 2022, followed by a gradual decline. The ratio remained relatively stable throughout 2023, hovering between 4.11 and 4.59, before entering a period of sustained contraction. A low of 3.53 was recorded in September 2025, marking the point of slowest turnover. However, a sharp reversal occurred in 2026, with the ratio climbing to 4.70 by June 2026.
Working Capital and Liquidity Implications
The downward trend in turnover observed between late 2023 and September 2025 suggests a strategic extension of the payment cycle to vendors, which typically serves to preserve cash flow and optimize working capital. The subsequent increase in the turnover ratio during the first two quarters of 2026 indicates a transition toward more rapid settlement of obligations, potentially reflecting changed supplier terms or a shift in liquidity management strategies.


Working Capital Turnover

Merck & Co. Inc., working capital turnover calculation (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Current assets
Less: Current liabilities
Working capital
 
Sales
Short-term Activity Ratio
Working capital turnover1
Benchmarks
Working Capital Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Working capital turnover = (SalesQ2 2026 + SalesQ1 2026 + SalesQ4 2025 + SalesQ3 2025) ÷ Working capital
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The analysis of operating activity reveals a volatile relationship between working capital and sales from March 2022 through June 2026. While sales figures demonstrate a gradual upward trajectory, the working capital turnover ratio is primarily driven by significant fluctuations in the working capital balance rather than revenue growth.

Working Capital Trends
Working capital exhibited substantial volatility, characterized by two distinct periods of contraction and expansion. A notable decline occurred during 2023, with balances dropping to 6,474 million by December. This was followed by a period of aggressive expansion peaking in September 2025 at 18,929 million, before returning to a more stable range of approximately 8,070 to 8,948 million in the first half of 2026.
Sales Performance
Revenue remained relatively stable with a moderate growth trend. Sales ranged from a low of 13,830 million in December 2022 to a peak of 17,276 million in September 2025. The consistency of sales suggests that the fluctuations in the turnover ratio are not a result of revenue instability, but rather changes in short-term asset and liability management.
Working Capital Turnover Dynamics
The turnover ratio demonstrates an inverse correlation with the working capital balance. Efficiency peaks were observed in early 2024, reaching a high of 9.68 in March, which coincided with a period of lean working capital. Conversely, a significant decline in efficiency was recorded in late 2025, with the ratio falling to a period low of 3.39 in September. This drop aligns precisely with the peak in working capital, indicating a temporary decrease in the velocity of working capital utilization.
Operational Efficiency Recovery
Following the efficiency trough in late 2025, a rapid recovery is observed in 2026. The turnover ratio increased to 8.15 by March 2026 and remained elevated at 7.44 by June 2026. This recovery is attributed to a sharp reduction in working capital requirements relative to the maintained sales levels.


Average Inventory Processing Period

Merck & Co. Inc., average inventory processing period calculation (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data
Inventory turnover
Short-term Activity Ratio (no. days)
Average inventory processing period1
Benchmarks (no. days)
Average Inventory Processing Period, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ =

2 Click competitor name to see calculations.


The analysis of inventory management efficiency reveals a cyclical pattern characterized by an initial period of improvement, a prolonged phase of decline in turnover velocity, and a subsequent recovery toward the end of the observed period.

Inventory Turnover Trends
An initial increase in inventory turnover is observed from March 2022 (2.74) to a peak of 3.10 in September 2022. Following this peak, a consistent downward trajectory occurs over nearly three years, reaching a minimum ratio of 2.25 by June 2025. A reversal of this trend begins in the second half of 2025, with the turnover ratio climbing steadily to 2.90 by June 2026, nearly returning to early 2022 levels.
Average Inventory Processing Period
The processing period demonstrates a strong inverse correlation with turnover ratios. The duration required to process inventory decreased from 133 days in March 2022 to a low of 118 days in September 2022. This was followed by a sustained increase in the processing period, peaking at 162 days in June 2025. From September 2025 onward, a notable reduction in the processing cycle is evident, ending at 126 days by June 2026.
Operational Efficiency Insights
The period between December 2022 and June 2025 represents a phase of reduced operational efficiency, where inventory remained in the system significantly longer, increasing the average processing period by 38 days from its lowest point. The recovery observed between September 2025 and June 2026 suggests a successful optimization of inventory levels or an increase in sales velocity, resulting in a rapid contraction of the processing period from 160 days to 126 days.


Average Receivable Collection Period

Merck & Co. Inc., average receivable collection period calculation (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data
Receivables turnover
Short-term Activity Ratio (no. days)
Average receivable collection period1
Benchmarks (no. days)
Average Receivable Collection Period, Competitors2
AbbVie Inc.
Amgen Inc.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ =

2 Click competitor name to see calculations.


The analysis of short-term operating activity ratios reveals a fluctuating pattern in the efficiency of receivables management from March 2022 through June 2026. A consistent inverse correlation exists between the receivables turnover ratio and the average collection period, with notable cyclical peaks in efficiency occurring toward the end of the 2022 and 2023 calendar years.

Receivables Turnover Trends
The receivables turnover ratio showed an initial upward trajectory in 2022, rising from 5.49 in March to a peak of 6.27 by December. Throughout 2023, the ratio experienced volatility, dropping to 5.29 in June before recovering to 5.81 by year-end. From March 2024 through June 2026, the ratio generally trended downward or remained stagnant, fluctuating between 5.30 and 6.24, ultimately settling at 5.30, which indicates a reduction in the velocity of receivable conversions.
Average Receivable Collection Period Analysis
The average collection period fluctuated within a range of 58 to 69 days. Maximum efficiency was achieved in December 2022 and December 2023, where the collection period reached its minimum of 58 days. Conversely, a trend toward slower collections is observable from March 2024 onward, with the period frequently extending to 68 or 69 days. This suggests a gradual lengthening of the time required to collect outstanding payments from customers.
Cyclicality and Operational Insights
The data indicates a recurring seasonal or year-end pattern where collection periods shorten and turnover ratios increase during the fourth quarter of the year. However, this cyclical improvement became less pronounced in 2024 and 2025. By the end of the analyzed period in June 2026, the collection period returned to its maximum of 69 days, reflecting a decline in short-term liquidity efficiency compared to the optimal levels seen in late 2022.


Operating Cycle

Merck & Co. Inc., operating cycle calculation (quarterly data)

No. days

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data
Average inventory processing period
Average receivable collection period
Short-term Activity Ratio
Operating cycle1
Benchmarks
Operating Cycle, Competitors2
AbbVie Inc.
Amgen Inc.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= + =

2 Click competitor name to see calculations.


The operating cycle experienced a period of expansion followed by a contraction, characterized by significant fluctuations in inventory management and relative stability in receivables collection.

Average Inventory Processing Period
A fluctuating trend is observed, beginning at 133 days in March 2022 and decreasing to a low of 118 days by September 2022. Subsequently, a sustained upward trajectory occurred, with the period expanding consistently to a peak of 162 days in June 2025. This suggests a period of slower inventory turnover and increased holding times, followed by a sharp reduction to 126 days by June 2026.
Average Receivable Collection Period
The collection period remained relatively stable throughout the analyzed timeframe, oscillating within a narrow range between 58 and 69 days. The shortest collection period was recorded in December 2022 at 58 days, while the period concluded at 69 days in June 2026. This stability indicates a consistent efficiency in the conversion of accounts receivable into cash.
Operating Cycle
The overall operating cycle was primarily driven by the volatility of the inventory processing period. The cycle reached a minimum of 177 days in September 2022 and climbed to a peak of 230 days in June 2025. By June 2026, the cycle contracted to 195 days, effectively returning to levels similar to those observed at the start of the analysis period. The expansion between 2023 and 2025 represents a significant lengthening of the time required to convert raw materials into cash.


Average Payables Payment Period

Merck & Co. Inc., average payables payment period calculation (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data
Payables turnover
Short-term Activity Ratio (no. days)
Average payables payment period1
Benchmarks (no. days)
Average Payables Payment Period, Competitors2
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ =

2 Click competitor name to see calculations.


The analysis of short-term operating activity reveals a fluctuating pattern in the management of accounts payable from March 2022 through June 2026. A consistent inverse correlation is maintained between the payables turnover ratio and the average payables payment period, where decreases in turnover correspond directly with extensions in the payment cycle.

Initial Cycle Compression (2022)
Between March 2022 and September 2022, a downward trend in the average payables payment period is observed, decreasing from 86 days to a period low of 71 days. This movement coincides with an increase in payables turnover, which peaked at 5.16 during the same interval, indicating a temporary acceleration in the settlement of vendor obligations.
Period of Relative Stability (2023 to mid-2024)
Throughout 2023 and the first half of 2024, the payment cycle stabilized, fluctuating within a narrow range of 80 to 89 days. The payables turnover ratio remained relatively steady, generally hovering between 4.11 and 4.59, suggesting a consistent approach to working capital management during this phase.
Extended Payment Cycle (late 2024 to 2025)
A significant shift toward longer payment terms occurred starting in December 2024. The average payment period expanded from 86 days to a peak of 103 days by September 2025. This extension is mirrored by a decline in the payables turnover ratio, which reached its lowest point of 3.53 in September 2025, indicating a strategic or operational slowing of cash outflows to suppliers.
Recent Cycle Contraction (2026)
A sharp reversal is evident in the first half of 2026. The average payables payment period decreased from 98 days in December 2025 to 78 days by June 2026. This reduction is supported by a recovery in the payables turnover ratio, which rose to 4.70, marking a return to a more accelerated payment cadence.


Cash Conversion Cycle

Merck & Co. Inc., cash conversion cycle calculation (quarterly data)

No. days

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data
Average inventory processing period
Average receivable collection period
Average payables payment period
Short-term Activity Ratio
Cash conversion cycle1
Benchmarks
Cash Conversion Cycle, Competitors2
Amgen Inc.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= + =

2 Click competitor name to see calculations.


The Cash Conversion Cycle (CCC) exhibits notable volatility over the analyzed period, characterized by an expansion of the cycle through mid-2024 followed by a gradual contraction. The CCC reached a peak of 138 days during the first half of 2024, contrasting with a period low of 93 days in December 2022, and concluded the period at 117 days.

Average Inventory Processing Period
A sustained upward trend is evident from September 2022 (118 days) through June 2025, where the period peaked at 162 days. This expansion suggests a slowdown in inventory turnover. However, a significant reversal occurred in the final quarters of the analysis, with the period declining to 126 days by June 2026, indicating an improvement in inventory efficiency.
Average Receivable Collection Period
The collection period remained relatively stable throughout the duration, fluctuating within a narrow range between 58 and 69 days. Despite minor increases observed between 2023 and 2024, the consistency of these figures suggests a steady approach to credit management and receivable collections.
Average Payables Payment Period
Payment terms to suppliers showed a general increase, peaking at 103 days in September 2025. This trend of extending payables served as a partial offset to the increasing inventory processing times. Toward the end of the period, a contraction is observed, with the payment period decreasing to 78 days by June 2026.

The fluctuations in the Cash Conversion Cycle were predominantly driven by the inventory processing period, which was the most volatile component of the operating cycle. While the strategic extension of the payables payment period mitigated some of the liquidity pressure during 2024 and 2025, the simultaneous reduction in both inventory days and payables days in 2026 led to a normalized CCC of 117 days.